Agarwal Arjun 4
4 · Oruka Therapeutics, Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Oruka (ORKA) SVP Finance Arjun Agarwal Sells Shares
What Happened
Arjun Agarwal, Senior Vice President, Finance at Oruka Therapeutics (ORKA), disposed of 395 shares on 2026-03-16 in an open-market/private sale at $41.30 per share, for a total of $16,313. The sale was effected as part of an automatic sell-to-cover to satisfy tax withholding obligations tied to vested restricted stock units.
Key Details
- Transaction date and price: 2026-03-16 — 395 shares sold at $41.30/share (total $16,313).
- Reason/footnote: Sale effected pursuant to Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding on RSU vesting (Footnote F1).
- Shares owned after transaction: Not disclosed in the Form 4 filing.
- Filing: Report filed 2026-03-17 for the 2026-03-16 transaction — within typical SEC Form 4 timing requirements (timely).
Context
Sell-to-cover transactions are common when restricted stock units vest and do not necessarily indicate an insider’s view on the company’s prospects; they are routine tax-withholding actions rather than discretionary sales. For investors, purchases generally carry more weight as a positive signal than routine sales like this one.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-16$41.30/sh−395$16,313→ 18,863 total
Footnotes (1)
- [F1]The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.